EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice

Frank Jagusch iD, Elena Redl, Christoph Theyer iD, Atbin Djamshidian, Alessandra Fanciulli iD, Werner Poewe, Philipp Mahlknecht iD, Beatrice Heim iD, Klaus Seppi, Florian Krismer iD

Movement Disorders Clinical Practice · 2026

DOI: 10.1002/mdc3.70656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, 2026. Verfasst von Frank Jagusch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. Hauptthemen laut MEDLINE: 3-Iodobenzylguanidine, Supranuclear Palsy, Progressive, Parkinsonian Disorders, Multiple System Atrophy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reduced cardiac uptake on 123 Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions.

Objectives

This study investigated factors limiting the clinical applicability of MIBG scintigraphy in everyday clinical practice.

Methods

Patient records (2021–2022) were retrospectively reviewed, independent of whether MIBG scintigraphy was performed, for comorbidities and concomitant medication confounding its interpretation.

Results

Six hundred ninety five patients (640 Parkinson's disease, 22 multiple system atrophy, 33 progressive supranuclear palsy) were included. Factors potentially influencing cardiac MIBG binding were present in 55.3% with 18.1% exhibiting multiple factors. Medications with known drug‐tracer interactions were found in 46.9% and comorbidities associated with reduced cardiac MIBG uptake in 20.9%.

Conclusions

The clinical utility of MIBG scintigraphy is frequently restricted by medications and comorbidities highlighting the need of careful planning in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

3-IodobenzylguanidineSupranuclear Palsy, ProgressiveParkinsonian DisordersMultiple System AtrophyMyocardial Perfusion ImagingParkinson DiseaseHeartHumansFemaleMaleRetrospective StudiesAgedRadiopharmaceuticalsMiddle AgedRadionuclide Imaging

Stichwörter der Autor:innen

123I‐meta‐iodobenzylguanidine (123I‐MIBG) myocardial scintigraphyParkinson's diseaseclinical applicationsmultiple system atrophyprogressive supranuclear palsy

Substanzen

3-IodobenzylguanidineRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.

ORCID-Profile: Frank Jagusch, Christoph Theyer, Alessandra Fanciulli, Philipp Mahlknecht, Beatrice Heim, Florian Krismer

Zitieren

APA

Jagusch, F., Redl, E., Theyer, C., Djamshidian, A., Fanciulli, A., Poewe, W., Mahlknecht, P., Heim, B., Seppi, K., & Krismer, F. (2026). Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70656

Vancouver

Jagusch F, Redl E, Theyer C, Djamshidian A, Fanciulli A, Poewe W, et al. Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70656

BibTeX
@article{Jagusch2026,
  author = {Jagusch, Frank and Redl, Elena and Theyer, Christoph and Djamshidian, Atbin and Fanciulli, Alessandra and Poewe, Werner and Mahlknecht, Philipp and Heim, Beatrice and Seppi, Klaus and Krismer, Florian},
  title = {Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice},
  journal = {Movement Disorders Clinical Practice},
  year = {2026},
  doi = {10.1002/mdc3.70656}
}
Kostenlos starten →